Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinobufacini intraperitoneal perfusion for malignant ascites in advanced gastrointestinal cancer
ChiCTR-IPR-15005907Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine East Hospital
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cinobufacini and fluorouracil in malignant ascites and gastrointestinal cancer (2 arms), sponsored by Beijing University of Chinese Medicine East Hospital. Primary endpoint: Malignant ascites volume in gastrointestinal tumors. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
cinobufacinifluorouracil
03
Conditions
malignant ascitesgastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR-IPR-15005907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005907.